2022-01-18

Realheart provides clarification on UAE media reports

Scandinavian Real Heart AB would like to make the following comment regarding information in the Arabic media tonight:

It is correct that we are in discussions with a party in the United Arab Emirates (UAE) about a possible investment in Realheart and the opening of a representative office in Sharjah, but no agreement has been reached.

The founder, Dr Azad Najar, is currently in the UAE for participation in the International Conference of Pharmacy and Medicine.

This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-01-2022 20:44 CET.

For more information please contact:

Azad Najar

Phone: +46(0)736 673 463

e-mail: azad.najar@realheart.se 

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.pieper@realheart.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.

Realheart provides clarification on UAE media reports